REBISCAN, LLC
Portable point-of-care diagnostic devices using NPS technology for rapid disease detection and triage
- Sector
- Medtech
- Headquarters
- Cambridge, MA
- Latest Form D
- $2.2M, Aug 2017
- Total capital
- $5.9M
- Federal grants
- $3.7M
- 11 awards · 2015–2023
- Rank in peer group#248 of 538
- Private capital raised
- $2.2M
- 1 Form D · last Aug 2017
- 110 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- None on recordNo USPTO grants. Applications publish after 18 months.
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · TBI Identification and Monitoring Through Retinal Scanning$518K
- Federal grantHealth and Human S · Phase II · TBI identification and monitoring through retinal scanning$518K
- Federal grantHealth and Human S · Phase I · A new generation, enhanced, corneal-birefringence-independent retinalscanning device for pediatric vision disorders using polarization modulation$225K
- Federal grantHealth and Human S · Phase I · TBI identification and monitoring through retinal scanning$149K
- Federal grantHealth and Human S · Phase II · Deploying retinal birefringence imaging in to the clinic for pediatric vision screening$441K
- Federal grantHealth and Human S · Phase II · Deploying retinal birefringence imaging in to the clinic for pediatric vision screening$542K
- Federal grantHealth and Human S · Phase II · Improving quality vision outcomes in the managed care setting while reducing cost by use of accurate, automated screening$511K
- Private capital raisedForm D · SEC · 1st filing$2.2M
Show 4 earlier federal awards
- Federal grantHealth and Human S · Phase I · Retinal birefringence imaging for pediatric vision screening$149K
- Federal grantHealth and Human S · Phase II · Supplemental support to remove FDA restriction on language for usage$25K
- Federal grantHealth and Human S · Phase II · Improving quality vision outcomes in the managed care setting while reducing cost by use of accurate, automated screening$520K
- Federal grantHealth and Human S · Phase II · Improving quality vision outcomes in the managed care setting while reducing cost by use of accurate, automated screening$145K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
24months
from REBISCAN, LLC’s first federal award to its first private round.
- First federal award · Sep 2015
- Health and Human S · $145K
- First Form D · Aug 2017
- $2.2M · 1st Form D
- Awards before first raise
- 4 awards
An association in public records, not a cause or a prediction.
Standing among 538 peers
Line = medianMedtech · Device
- Federal grants#248 · top 46%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Justin ShakaResearcherExecutive Officer, DirectorLinked by $2.9M in grants as PI
- David HunterDirectorNamed in SEC Form D filings
- Hooks JohnstonDirectorNamed in SEC Form D filings
- Jeffery CraigDirectorNamed in SEC Form D filings
- Jeffrey MortensenExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
No granted patents are on record.
USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.
Checked: USPTO granted patents and published applications · Oct 23, 2026
Related companies, and why
- CYTOVERIS INCSimilar federal contract value in Medtech · null in contracts
- Potrero Medical, Inc.Similar federal contract value in Medtech · null in contracts
- ALDATU BIOSCIENCES INCSimilar federal contract value in Medtech · null in contracts
- Applied Research and PhotonicsSimilar federal contract value in Medtech · null in contracts
- CHRONO THERAPEUTICS, INC.Similar federal contract value in Medtech · null in contracts
- HEMEX HEALTH INCSimilar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .